読み込み中
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
前日終値
$2.79
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
日中レンジ
現在 $2.79
52週レンジ
現在 $2.79
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
54
まちまち
リスク
71
高リスク
モメンタム
51
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
日中レンジ
現在 $2.79
52週レンジ
現在 $2.79
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 1275万 USD | — | — | — | — |
| 粗利益 | −1275万 USD | — | — | — | — |
| 研究開発 | 1.32億 USD | 2.09億 USD | 2.2億 USD | 2.01億 USD | 3.06億 USD |
| 販売・一般管理 | 4429.6万 USD | 6404万 USD | 7329.9万 USD | 7156.1万 USD | 5041万 USD |
| 営業費用 | 1.78億 USD | 2.73億 USD | 2.93億 USD | 2.73億 USD | 3.57億 USD |
| 受取利息 | 384.8万 USD | 1047.1万 USD | 993.8万 USD | 376.2万 USD | 67.6万 USD |
| 減価償却費と償却費 | 1275万 USD | 1550万 USD | 2455.7万 USD | 1562.5万 USD | 1107万 USD |
| 営業利益 | −1.91億 USD | −2.73億 USD | −2.93億 USD | −2.73億 USD | −3.57億 USD |
| 純利益 | −2.44億 USD | −2.67億 USD | −2.83億 USD | −2.69億 USD | −3.56億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$7.00
上昇余地（150.90%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2419.39万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1544.5万0.16%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1269.07万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF761.22万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO444.22万0.03%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO408.15万0.02%180億 USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB398.76万0.04%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA279.79万0.01%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
